No Data
No Data
Is Avidity Biosciences Inc. (RNA) the Best Performing Small-Cap Stock in 2024?
Avidity Biosciences to Participate in Upcoming Investor Conference
Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases
Avidity Biosciences Price Target Announced at $59.00/Share by Goldman Sachs
Goldman Sachs Initiates Avidity Biosciences at Buy
Goldman Sachs Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $59
Goldman Sachs analyst Corinne Johnson initiates coverage on $Avidity Biosciences(RNA.US)$ with a buy rating, and sets the target price at $59.According to TipRanks data, the analyst has a success